Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept

Arthritis Care and Research

Volumn 66, Issue 2, 2014, Pages 253-262

  Klotsche, Jens ^a   Minden, Kirsten ^a   Thon, Angelika ^b   Ganser, Gerd ^c   Urban, Andreas ^d   Horneff, Gerd ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Abt Kinder und Jugendrheumatologie   (Germany)

^d Klinikum Amberg   (Germany)

^e Asklepios Clinic Sankt Augustin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HLA B27 ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PEDIATRIC QUALITY OF LIFE INVENTORY; PREDICTION; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VOMITING;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893373104     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22112     Document Type: Article

References (41)

1. Packham JC, Hall MA,. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41: 1428-35.
2. Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003; 30: 386-93.
3. Solari N, Viola S, Pistorio A, Magni-Manzoni S, Vitale R, Ruperto N, et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008; 59: 1571-9.
4. Moorthy LN, Peterson MG, Harrison MJ, Onel KB, Lehman TJ,. Physical function assessment tools in pediatric rheumatology. Pediatr Rheumatol Online J 2008; 6: 9.
5. Gare BA, Fasth A,. The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. J Rheumatol 1995; 22: 308-19.
6. Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID,. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003; 48: 767-75.
7. Ruperto N, Buratti S, Duarte-Salazar C, Pistorio A, Reiff A, Bernstein B, et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Rheum 2004; 51: 458-64.
8. Brunner HI, Giannini EH,. Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol 2003; 15: 602-12.
9. Seid M,. Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis [editorial]. Arthritis Care Res (Hoboken) 2012; 64: 652.
10. Burgos-Vargas R,. Assessment of quality of life in children with rheumatic disease. J Rheumatol 1999; 26: 1432-5.
11. Tucker LB,. Whose life is it anyway? Understanding quality of life in children with rheumatic diseases. J Rheumatol 2000; 27: 8-11.
12. World Health Organization. Final report: Regional Working Group on Health Needs of Adolescents. Manila (Philippines): World Health Organization; 1980.
13. Varni JW, Seid M, Smith Knight T, Burwinkle T, Brown J, Szer IS,. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002; 46: 714-25.
14. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-9.
15. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009; 68: 635-41.
16. Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ,. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 393-9.
17. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
18. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
19. Wallace CA, Ruperto N, Giannini E,. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
20. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
21. Foeldvari I, Ruperto N, Dressler F, Hafner R, Kuster RM, Michels H, et al. The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19 Suppl: S71-5.
22. Dempster H, Porepa M, Young N, Feldman BM,. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 2001; 44: 1768-74.
23. Haverman L, Grootenhuis MA, van den Berg JM, van Veenendaal M, Dolman KM, Swart JF, et al. Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a web-based survey. Arthritis Care Res (Hoboken) 2012; 64: 694-703.
24. Laird NM, Ware JH,. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.
25. Hedeker D, Gibbons RD,. Application of random-effects pattern mixture models for missing data in longitudinal studies. Psychol Methods 1997; 2: 64-78.
26. Muthen B,. Latent variable analysis: growth mixture modeling and related techniques for longitudinal data. In:, Kaplan D, editor. Handbook of quantitative methodology for the social sciences. Newbury Park (CA): Sage Publications; 2004. p. 345-68.
27. Nylund KL, Asparouhov T, Muthen B,. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Modeling 2007; 14: 535-69.
28. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011; 306: 2340-7.
29. Ringold S, Seidel KD, Koepsell TD, Wallace CA,. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 2009; 48: 972-7.
30. Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010; 69: 138-42.
31. Ringold S, Wallace CA, Rivara FP,. Health-related quality of life, physical function, fatigue, and disease activity in children with established polyarticular juvenile idiopathic arthritis. J Rheumatol 2009; 36: 1330-6.
32. Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010; 62: 1542-51.
33. Gutierrez-Suarez R, Pistorio A, Cespedes Cruz A, Norambuena X, Flato B, Rumba I, et al. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas: the PRINTO multinational quality of life cohort study. Rheumatology (Oxford) 2007; 46: 314-20.
34. Amine B, Rostom S, Benbouazza K, Abouqal R, Hajjaj-Hassouni N,. Health related quality of life survey about children and adolescents with juvenile idiopathic arthritis. Rheumatol Int 2009; 29: 275-9.
35. Brunner HI, Klein-Gitelman MS, Miller MJ, Trombley M, Baldwin N, Kress A, et al. Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting. Arthritis Rheum 2004; 51: 763-73.
36. Varni JW, Burwinkle TM, Lane MM,. Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application. Health Qual Life Outcomes 2005; 3: 34.
37. Riddle R, Ryser CN, Morton AA, Sampson JD, Browne RH, Punaro MG, et al. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol 2006; 31: 262-71.
38. Murray KJ, Lovell DJ,. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002; 16: 361-78.
39. Van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G,. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007; 25: 480-5.
40. Varni JW, Limbers CA, Burwinkle TM,. How young can children reliably and validly self-report their health-related quality of life? An analysis of 8,591 children across age subgroups with the PedsQL 4.0 generic core scales. Health Qual Life Outcomes 2007; 5: 1.
41. Blazeby JM, Williams MH, Alderson D, Farndon JR,. Observer variation in assessment of quality of life in patients with oesophageal cancer. Br J Surg 1995; 82: 1200-3.